Glatiramer Acetate
Tóm tắt
Từ khóa
Tài liệu tham khảo
Aharoni R, Eilam R, Domev H, Labunskay G, Sela M, Arnon R (2005) The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc Natl Acad Sci USA 102:19045–19050
Aharoni R, Herschkovitz A, Eilam R, Shen S, Vainshtein A, Blumberg-Hazan M, Bruck W, Arnon R (2007) Prevention of demyelination and possible remyelination by glatiramer acetate in EAE mice visualised by the novel wet SEM technology and immunohistochemistry. Neurology 68:A316–A317
Aharoni R, Kayhan B, Eilam R, Sela M, Arnon R (2003) Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci USA 100:14157–14162
Aharoni R, Teitelbaum D, Arnon R, Sela M (1999) Copolymer 1 acts against the immunodominant epitope 82–100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc Natl Acad Sci USA 96:634–639
Aharoni R, Teitelbaum D, Sela M, Arnon R (1998) Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. J Neuroimmunol 91:135–146
Arnon R (1996) The development of Cop 1 (Copaxone), an innovative drug for the treatment of multiple sclerosis: personal reflections. Immunology Letters 50:1–15
Barkhof F, Karas GB, van Walderveen MA (2000) T1 hypointensities and axonal loss. Neuroimaging Clinics of North America 10:739–752, ix
Besser M, Wank R (1999) Cutting edge: clonally restricted production of the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune cells and Th1/Th2-polarized expression of their receptors. J Immunol 162:6303–6306
Bornstein MB, Miller A, Slagle S, Weitzman M, Crystal H, Drexler E, Keilson M, Merriam A, Wassertheil-Smoller S, Spada V, et al. (1987) A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 317:408–414
Braun A, Lommatzsch M, Mannsfeldt A, Neuhaus-Steinmetz U, Fischer A, Schnoy N, Lewin GR, Renz H (1999) Cellular sources of enhanced brain-derived neurotrophic factor production in a mouse model of allergic inflammation. Am J Respir Cell Mol Biol 21:537–546
Chen M, Conway K, Johnson KP, Martin R, Dhib-Jalbut S (2002) Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 years. J Neurol Sci 201:71–77
Chen M, Valenzuela RM, Dhib-Jalbut S (2003) Glatiramer acetate-reactive T cells produce brain-derived neurotrophic factor. J Neurol Sci 215:37–44
Comi G, Filippi M, Wolinsky JS (2001) European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging – measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 49:290–297
Filippi M, Rovaris M, Rocca MA, Sormani MP, Wolinsky JS, Comi G (2001) Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes”. Neurology 57:731–733
Ford CC, Johnson KP, Lisak RP, Panitch HS, Shifronis G, Wolinsky JS (2006) A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler (Houndmills, Basingstoke, England) 12:309–320
Fridkis-Hareli M, Neveu JM, Robinson RA, Lane WS, Gauthier L, Wucherpfennig KW, Sela M, Strominger JL (1999) Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules. J Immunol 162:4697–4704
Fridkis-Hareli M, Strominger JL (1998) Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules. J Immunol 160:4386–4397
Ge Y, Grossman RI, Udupa JK, Fulton J, Constantinescu CS, Gonzales-Scara no F, Babb JS, Mannon LJ, Kolson DL, Cohen JA (2000) Glatiramer acetate (Copaxone) treatment in relapsingremitting MS: quantitative MR assessment. Neurology 54:813–817
Gilgun-Sherki Y, Panet H, Holdengreber V, Mosberg-Galili R, Offen D (2003) Axonal damage is reduced following glatiramer acetate treatment in C57/bl mice with chronic-induced experimental autoimmune encephalomyelitis. Neurosci Res 47:201–207
Gran B, Tranquill LR, Chen M, Bielekova B, Zhou W, Dhib-Jalbut S, Martin R (2000) Mechanisms of immunomodulation by glatiramer acetate. Neurology 55:1704–1714
Holmoy T, Skorstad G, Hestvik A, Vartdal F (2007) Multiple Sclerosis: Phenotype of Cerebrospinal Fluid T Cells Specific for Glatiramer Acetate. Neurology 68:A19–A20
Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45:1268–1276
Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JS (1998) Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 50:701–708
Kerschensteiner M, Gallmeier E, Behrens L, Leal VV, Misgeld T, Klinkert WE, Kolbeck R, Hoppe E, Oropeza-Wekerle RL, Bartke I, Stadelmann C, Lassmann H, Wekerle H, Hohlfeld R (1999) Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? The Journal of Experimental Medicine 189:865–870
Kerschensteiner M, Stadelmann C, Dechant G, Wekerle H, Hohlfeld R (2003) Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann Neurol 53:292–304
Khan O, Mackenzie M, Shen Y, Zak I, Latif Z, Caon C (2007) Combined Brain MTR and H-MRS Multi-Modality Approach To Investigate Mechanism of Action of Interferon Beta and Glatiramer Acetate in RRMS. Neurology 68(Suppl 1):A57
Khan O, Shen Y, Caon C, Bao F, Ching W, Reznar M, Buccheister A, Hu J, Latif Z, Tselis A, Lisak R (2005) Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler (Houndmills, Basingstoke, England) 11:646–651
Khan O, Shen Y, Hu J, Ching W, Caon C, Reznar M, Latif Z, Tselis A, Lisak R (2005) Sustained effect of glatiramer acetate on cerebral axonal recovery in relapsing-remitting MS: results after three years of serial brain magnetic resonance spectroscopy examination. J Neurol 252:127–128
Khan O, Shen Y, Mackenzie M, Caon C, Bao F, Latif Z, Tselis A, Lisak R (2006) Prospective long-term study of proton brain magnetic resonance spectroscopy (MRS) in relapsing-remitting MS (RRMS): Effect of glatiramer acetate on axonal injury. Mult Scler 12(Suppl 1):S39
Kornek B, Storch MK, Weissert R, Wallstroem E, Stefferl A, Olsson T, Linington C, Schmidbauer M, Lassmann H (2000) Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 157:267–276
Maier K, Kuhnert AV, Taheri N, Sattler MB, Storch MK, Williams SK, Bahr M, Diem R (2006) Effects of glatiramer acetate and interferon-beta on neurodegeneration in a model of multiple sclerosis: a comparative study. Am J Pathol 169:1353–1364
Martinelli Boneschi F, Rovaris M, Johnson KP, Miller A, Wolinsky JS, Ladkani D, Shifroni G, Comi G, Filippi M (2003) Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. Mult Scler (Houndmills, Basingstoke, England) 9:349–355
Multiple Sklerose Therapie Konsensus Gruppe (MSTKG), Rieckmann P (2006) Immunmodulatorische Stufentherapie der Multiplen Sklerose. Der Nervenarzt 77:1506–1518
Narayanan S, Caramanos Z, Arnold D (2004) The effect of glatiramer acetate treatment on axonal integrity in multiple sclerosis. Mult Scler 10(Suppl 1):S256
Neuhaus O, Archelos JJ, Hartung HP (2003) Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. Trends Pharmacol Sci 24:131–138
Neuhaus O, Farina C, Wekerle H, Hohlfeld R (2001) Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 56:702–708
Neuhaus O, Farina C, Yassouridis A, Wiendl H, Then Bergh F, Dose T, Wekerle H, Hohlfeld R (2000) Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci USA 97:7452–7457
Pette M, Fujita K, Kitze B, Whitaker JN, Albert E, Kappos L, Wekerle H (1990) Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology 40:1770–1776
Qin Y, Zhang DQ, Prat A, Pouly S, Antel J (2000) Characterization of T cell lines derived from glatiramer-acetate-treated multiple sclerosis patients. J Neuroimmunol 108:201–206
Richert N, Bagnato F, Howard T, Blevins G, Ostuni J, Frank J, McFarland H (2003) Whole brain magnetization transfer analysis of relapsing-remitting multiple sclerosis patients treated with IFNB-1b or glatiramer acetate. Mult Scler 9(Suppl 1):S64
Rovaris M, Comi G, Rocca MA, Wolinsky JS, Filippi M (2001) Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. Brain 124:1803–1812
Sormani MP, Rovaris M, Valsasina P, Wolinsky JS, Comi G, Filippi M (2004) Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. Neurology 62:1432–1434
Stadelmann C, Kerschensteiner M, Misgeld T, Bruck W, Hohlfeld R, Lassmann H (2002) BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain 125:75–85
Teitelbaum D, Arnon R, Sela M (1997) Cop 1 as a candidate drug for multiple sclerosis. J Neural Transm 49:85–91
Teitelbaum D, Meshorer A, Hirshfeld T, Arnon R, Sela M (1971) Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol 1:242–248
Truyen L, van Waesberghe JH, van Walderveen MA, van Oosten BW, Polman CH, Hommes OR, Ader HJ, Barkhof F (1996) Accumulation of hypointense lesions (“black holes”) on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 47:1469–1476
van Waesberghe JH, Kamphorst W, De Groot CJ, van Walderveen MA, Castelijns JA, Ravid R, Lycklama a Nijeholt GJ, van der Valk P, Polman CH, Thompson AJ, Barkhof F (1999) Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 46:747–754
van Walderveen MA, Barkhof F, Pouwels PJ, van Schijndel RA, Polman CH, Castelijns JA (1999) Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. Ann Neurol 46:79–87
Vieira PL, Heystek HC, Wormmeester J, Wierenga EA, Kapsenberg ML (2003) Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J Immunol 170:4483–4488
Wolinsky JS, Comi G, Filippi M, Ladkani D, Kadosh S, Shifroni G (2002) Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained. Neurology 59:1284–1286
Wolinsky JS, Narayana PA, Johnson KP (2001) United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center. Mult Scler (Houndmills, Basingstoke, England) 7:33–41
Ziemssen T, Kumpfel T, Klinkert WE, Neuhaus O, Hohlfeld R (2002) Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain 125:2381–2391